| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/22/2023 | 73.58% | Wedbush | → $23 | Initiates Coverage On | → Outperform |
| 09/28/2023 | 81.13% | Raymond James | → $24 | Initiates Coverage On | → Outperform |
What is the target price for Dianthus Therapeutics (DNTH)?
The latest price target for Dianthus Therapeutics (NASDAQ: DNTH) was reported by Wedbush on November 22, 2023. The analyst firm set a price target for $23.00 expecting DNTH to rise to within 12 months (a possible 73.58% upside). 2 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Dianthus Therapeutics (DNTH)?
The latest analyst rating for Dianthus Therapeutics (NASDAQ: DNTH) was provided by Wedbush, and Dianthus Therapeutics initiated their outperform rating.
When is the next analyst rating going to be posted or updated for Dianthus Therapeutics (DNTH)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Dianthus Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Dianthus Therapeutics was filed on November 22, 2023 so you should expect the next rating to be made available sometime around November 22, 2024.
Is the Analyst Rating Dianthus Therapeutics (DNTH) correct?
While ratings are subjective and will change, the latest Dianthus Therapeutics (DNTH) rating was a initiated with a price target of $0.00 to $23.00. The current price Dianthus Therapeutics (DNTH) is trading at is $13.25, which is within the analyst's predicted range.